New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
15:50 EDTDUSADusa Pharmaceuticals says Phase 2 clinical trial statistically significant
Dusa Pharmaceuticals reported preliminary results of a Phase 2 clinical trial investigating the use of the Levulan Kerastick in conjunction with BLU-U blue light illumination for the treatment of actinic keratoses of the face and scalp when utilizing short drug incubation. The study demonstrated that treatment with Levulan Kerastick after incubating for one, two or three hours resulted in a statistically significant number of patients with complete lesion clearance and a statistically significant reduction in AK lesion count when compared to treatment with vehicle 12 weeks post treatment, the company said.
News For DUSA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for DUSA

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use